Cardiac and renal outcomes of direct oral anticoagulants in patients with atrial fibrillation
European Journal of Clinical Investigation · 2024-01 · 54 (1)
DOI: 10.1111/eci.14086 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 27.08.2023. Verfasst von Yu-Ting Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Wan Fang Hospital.
Abstract (Originalsprache)
Background
Oral anticoagulation therapy with warfarin or direct oral anticoagulants (DOACs) is the mainstay for stroke prevention in patients with non‐valvular atrial fibrillation (AF). The DOACs might have a lower risk of declining renal function than warfarin. This study aimed to compare renal outcomes among rivaroxaban, edoxaban, dabigatran, and warfarin.
Method
This cohort study identified 2203 adults with AF who started anticoagulation therapy between 1 July 2013 and 31 December 2020, in a clinical database at a single centre. Inverse probability of treatment weighting was adopted to balance baseline characteristics among four anticoagulants treatment groups. The primary outcome was a composite of cardiac and renal outcomes, involving a ≥30% decline in estimated glomerular filtration rate (eGFR), renal failure and cardiovascular death.
Results
After propensity score weighting, dabigatran was associated with significantly lower risks of a ≥30% decline in eGFR (hazard ratio [HR]: .69, 95% confidence interval [CI]: .497–.951, p = .0237), doubling of the serum creatinine level (HR: .49, 95% CI: .259–.927, p = .0282) and the cardiac and renal outcome composite (HR: .67, 95% CI: .485–.913, p = .0115) than warfarin. Rivaroxaban and edoxaban did not show significant protective effects on renal outcomes compared to warfarin.
Conclusion
In this study, patients treated with dabigatran had significantly reduced risks of declining renal function and composite cardiac and renal events than those treated with warfarin. However, rivaroxaban and edoxaban were not associated with lower risks of any renal outcomes than warfarin. More studies are warranted to investigate and compare the impact of renal function between different DOACs in patients with AF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
- School of Public Health, College of Public Health, Taipei Medical University, Taipei, Taiwan.
- Department of Medical Research, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
- Division of Cardiovascular Medicine, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
- Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
- Taipei Heart Institute, Taipei Medical University, Taipei, Taiwan.
ORCID-Profile: Jong-Shiuan Yeh
Förderung
- Wan Fang Hospital
Zitieren
APA
Wang, Y. T., Chen, J. H., Liao, S. F., Chen, Y. J., Lip, G. Y. H., & Yeh, J. S. (2024). Cardiac and renal outcomes of direct oral anticoagulants in patients with atrial fibrillation. European Journal of Clinical Investigation, 54(1). https://doi.org/10.1111/eci.14086
Vancouver
Wang YT, Chen JH, Liao SF, Chen YJ, Lip GYH, Yeh JS. Cardiac and renal outcomes of direct oral anticoagulants in patients with atrial fibrillation. European Journal of Clinical Investigation. 2024;54(1). doi:10.1111/eci.14086
BibTeX
@article{Wang2024,
author = {Wang, Yu-Ting and Chen, Jo-Hsin and Liao, Shu-Fen and Chen, Yu-Jen and Lip, Gregory Y H and Yeh, Jong-Shiuan},
title = {Cardiac and renal outcomes of direct oral anticoagulants in patients with atrial fibrillation},
journal = {European Journal of Clinical Investigation},
year = {2024},
volume = {54},
number = {1},
doi = {10.1111/eci.14086}
}
EUVIMED